ホーム › 非小細胞肺癌 › カリフォルニア州 › Fullerton
Fullerton、CAにおける非小細胞肺癌の臨床試験
Fullertonとその周辺地域（約30マイル以内）の拠点で、非小細胞肺癌に関する13件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
被験者募集中第1/2相
- Providence - St. Jude Medical Center /ID# 271414, Fullerton
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
被験者募集中第3相
- Providence St. Jude Medical Center ( Site 0106), Fullerton
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
被験者募集中第3相
- Providence Medical Foundation, Fullerton
- Providence St. Jude Medical Center, Fullerton
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
被験者募集中第2相
- Providence Medical Foundation, Fullerton
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
被験者募集中第3相
- Providence Medical Foundation, Fullerton
- Providence St. Jude Medical Center Virginia K. Crosson Cancer Center and Infusion Center, Fullerton
- Providence St. Jude Medical Center, Fullerton
- 他1件
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
被験者募集中第1/2相
- Providence Medical Foundation, Fullerton
- Providence St. Jude Medical Center - Virginia K. Crosson Cancer Center and Infusion Center, Fullerton
- Providence St. Jude Medical Center, Fullerton
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
被験者募集中第1相
- Providence Medical Foundation - Fullerton - Virginia K. Crosson Cancer Center, Fullerton
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
被験者募集中第3相
- Providence Medical Foundation, Fullerton
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
被験者募集中第3相
- St. Jude Medical Center, Fullerton
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
被験者募集中第1/2相
- Providence Medical Foundation, Fullerton
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
被験者募集中第1相
- Providence Medical Foundation, Fullerton
- Providence St. Jude Medical Center Virginia K Crosson and Infusion Center, Fullerton
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
被験者募集中第3相
- St. Jude Herritage Medical Group, Fullerton
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
被験者募集中
- St Jude Heritage Medical Group, Fullerton
他の都市における非小細胞肺癌の試験
- Houston, TX145件の研究
- New York City, NY121件の研究
- Arlington, VA104件の研究
- Nashville, TN97件の研究
- Boston, MA90件の研究
- Los Angeles, CA87件の研究
- St. Louis, MO73件の研究
- Chicago, IL61件の研究
- Baltimore, MD60件の研究
- San Antonio, TX59件の研究
- Columbus, OH57件の研究
- Washington, DC55件の研究
Fullertonにおける他の研究
- 乳がん9件の研究
- 卵巣がん6件の研究
- ループス5件の研究
- がん（全種類）5件の研究
- 肺がん4件の研究
- 膵臓がん4件の研究
- 胃癌3件の研究
- 食道癌3件の研究
- 悪性黒色腫3件の研究
- 頭頸部扁平上皮癌3件の研究
- 統合失調症3件の研究
- 大腸癌3件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。